speb/financial-data huggingface dataset:
CYTK income_statement (quarterly, 2026-03-31) — Total Expenses: 202973000.00
CYTK balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 2100046000.00
CYTK balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 434013000.00
CYTK balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 1900861000.00
CYTK income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -183618000.00
CYTK income_statement (quarterly, 2026-03-31) — Total Unusual Items: 1500000.00
CYTK income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 1500000.00
CYTK balance_sheet (quarterly, 2026-03-31) — Working Capital: 640280000.00
CYTO.V income_statement (annual, 2021-12-31) — Basic Average Shares: 53753356.00
CYTO.V income_statement (annual, 2021-12-31) — Basic EPS: -0.06
CYTO.V income_statement (annual, 2021-12-31) — Diluted Average Shares: 53753356.00
CYTO.V income_statement (annual, 2021-12-31) — Diluted EPS: -0.06
CYTO.V cash_flow (annual, 2021-12-31) — Other Non Cash Items: 1000.00
CYTO.V income_statement (annual, 2022-12-31) — +Operating Expense: 792244.00
CYTO.V income_statement (annual, 2022-12-31) — +Total Revenue: 0.00
CYTO.V balance_sheet (annual, 2022-12-31) — Accounts Payable: 112577.00
CYTO.V balance_sheet (annual, 2022-12-31) — Accounts Receivable: 4419.00
CYTO.V balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -996923.00
CYTO.V income_statement (annual, 2022-12-31) — Basic Average Shares: 53753356.00
CYTO.V income_statement (annual, 2022-12-31) — Basic EPS: -0.01
CYTO.V cash_flow (annual, 2022-12-31) — Beginning Cash Position: 187110.00
CYTO.V cash_flow (annual, 2022-12-31) — Capital Expenditure: -380808.00
CYTO.V balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 107892.00
CYTO.V balance_sheet (annual, 2022-12-31) — Capital Stock: 15442692.00
CYTO.V balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 2246338.00
CYTO.V balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 2246338.00
CYTO.V balance_sheet (annual, 2022-12-31) — Cash Financial: 2246338.00
CYTO.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 4411569.00
CYTO.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -4482705.00
CYTO.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -46472.00
CYTO.V cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: -7972.00
CYTO.V cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: 20783.00
CYTO.V cash_flow (annual, 2022-12-31) — Change In Receivables: -85681.00
CYTO.V cash_flow (annual, 2022-12-31) — Change In Working Capital: -72870.00
CYTO.V cash_flow (annual, 2022-12-31) — Changes In Account Receivables: -114418.00
CYTO.V cash_flow (annual, 2022-12-31) — Changes In Cash: -117608.00
CYTO.V balance_sheet (annual, 2022-12-31) — Common Stock: 15442692.00
CYTO.V balance_sheet (annual, 2022-12-31) — Common Stock Equity: 3451386.00
CYTO.V cash_flow (annual, 2022-12-31) — Common Stock Issuance: 5000000.00
CYTO.V balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 18000.00
CYTO.V balance_sheet (annual, 2022-12-31) — Current Assets: 2754669.00
CYTO.V balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 107892.00
CYTO.V balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 107892.00
CYTO.V balance_sheet (annual, 2022-12-31) — Current Liabilities: 238469.00
CYTO.V cash_flow (annual, 2022-12-31) — Depreciation: 364552.00
CYTO.V cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 364552.00
CYTO.V income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 364552.00
CYTO.V cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 364552.00
CYTO.V income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 364552.00
CYTO.V income_statement (annual, 2022-12-31) — Depreciation Income Statement: 364552.00
CYTO.V income_statement (annual, 2022-12-31) — Diluted Average Shares: 53753356.00
CYTO.V income_statement (annual, 2022-12-31) — Diluted EPS: -0.01
CYTO.V income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -706206.00
CYTO.V income_statement (annual, 2022-12-31) — EBIT: -792244.00
CYTO.V income_statement (annual, 2022-12-31) — EBITDA: -792244.00
CYTO.V income_statement (annual, 2022-12-31) — Earnings From Equity Interest: -41866.00
CYTO.V cash_flow (annual, 2022-12-31) — End Cash Position: 69502.00
CYTO.V cash_flow (annual, 2022-12-31) — Financing Cash Flow: 4411569.00
CYTO.V cash_flow (annual, 2022-12-31) — Free Cash Flow: -46472.00
CYTO.V balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: 2463140.00
CYTO.V income_statement (annual, 2022-12-31) — General And Administrative Expense: 708428.00
CYTO.V balance_sheet (annual, 2022-12-31) — Gross PPE: 1932108.00
CYTO.V balance_sheet (annual, 2022-12-31) — Hedging Assets Current: 256500.00
CYTO.V income_statement (annual, 2022-12-31) — Interest Expense: 20136.00
CYTO.V income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 20136.00
CYTO.V income_statement (annual, 2022-12-31) — Interest Income: 86038.00
CYTO.V income_statement (annual, 2022-12-31) — Interest Income Non Operating: 86038.00
CYTO.V cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 20136.00
CYTO.V cash_flow (annual, 2022-12-31) — Interest Received Cfi: 42295.00
CYTO.V balance_sheet (annual, 2022-12-31) — Invested Capital: 3451386.00
CYTO.V cash_flow (annual, 2022-12-31) — Investing Cash Flow: -4482705.00
CYTO.V cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 5000000.00
CYTO.V balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 0.00
CYTO.V balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 0.00
CYTO.V cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -147865.00
CYTO.V balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 248850.00
CYTO.V cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 5000000.00
CYTO.V income_statement (annual, 2022-12-31) — Net Income: -706206.00
CYTO.V income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -706206.00
CYTO.V income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -706206.00
CYTO.V income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -706206.00
CYTO.V income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -706206.00
CYTO.V cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -706206.00
CYTO.V income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -706206.00
CYTO.V income_statement (annual, 2022-12-31) — Net Interest Income: 86038.00
CYTO.V cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -4525000.00
CYTO.V cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -147865.00
CYTO.V cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -147865.00
CYTO.V income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 86038.00
CYTO.V cash_flow (annual, 2022-12-31) — Net Other Financing Charges: -588431.00
CYTO.V balance_sheet (annual, 2022-12-31) — Net PPE: 935185.00
CYTO.V cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -380808.00
CYTO.V balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 3451386.00
CYTO.V income_statement (annual, 2022-12-31) — Normalized EBITDA: -792244.00
CYTO.V income_statement (annual, 2022-12-31) — Normalized Income: -706206.00
CYTO.V cash_flow (annual, 2022-12-31) — Operating Cash Flow: -46472.00
CYTO.V income_statement (annual, 2022-12-31) — Operating Income: -792244.00
CYTO.V income_statement (annual, 2022-12-31) — Operating Revenue: 0.00
CYTO.V balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 53753356.00
CYTO.V income_statement (annual, 2022-12-31) — Other Gand A: 42131.00
CYTO.V income_statement (annual, 2022-12-31) — Other Income Expense: -41866.00
CYTO.V cash_flow (annual, 2022-12-31) — Other Non Cash Items: 66307.00
CYTO.V income_statement (annual, 2022-12-31) — Other Operating Expenses: 83816.00
CYTO.V balance_sheet (annual, 2022-12-31) — Other Properties: 1683258.00
CYTO.V income_statement (annual, 2022-12-31) — Other Taxes: -445023.00
CYTO.V balance_sheet (annual, 2022-12-31) — Payables: 112577.00
CYTO.V balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 130577.00
CYTO.V balance_sheet (annual, 2022-12-31) — Prepaid Assets: 51856.00
CYTO.V income_statement (annual, 2022-12-31) — Pretax Income: -706206.00
CYTO.V cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 0.00
CYTO.V cash_flow (annual, 2022-12-31) — Purchase Of Investment: -5300000.00
CYTO.V cash_flow (annual, 2022-12-31) — Purchase Of PPE: -380808.00
CYTO.V balance_sheet (annual, 2022-12-31) — Receivables: 199975.00
CYTO.V income_statement (annual, 2022-12-31) — Reconciled Depreciation: 364552.00
CYTO.V cash_flow (annual, 2022-12-31) — Repayment Of Debt: -147865.00
CYTO.V income_statement (annual, 2022-12-31) — Research And Development: 442614.00
CYTO.V balance_sheet (annual, 2022-12-31) — Retained Earnings: -14454446.00
CYTO.V income_statement (annual, 2022-12-31) — Salaries And Wages: 666297.00
CYTO.V cash_flow (annual, 2022-12-31) — Sale Of Investment: 775000.00
CYTO.V income_statement (annual, 2022-12-31) — Selling General And Administration: 708428.00
CYTO.V balance_sheet (annual, 2022-12-31) — Share Issued: 53753356.00
CYTO.V cash_flow (annual, 2022-12-31) — Stock Based Compensation: 666297.00
CYTO.V balance_sheet (annual, 2022-12-31) — Stockholders Equity: 3451386.00
CYTO.V balance_sheet (annual, 2022-12-31) — Tangible Book Value: 3451386.00
CYTO.V income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
CYTO.V income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
CYTO.V balance_sheet (annual, 2022-12-31) — Taxes Receivable: 195556.00
CYTO.V balance_sheet (annual, 2022-12-31) — Total Assets: 3689855.00
CYTO.V balance_sheet (annual, 2022-12-31) — Total Capitalization: 3451386.00
CYTO.V balance_sheet (annual, 2022-12-31) — Total Debt: 107892.00
CYTO.V balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 3451386.00
CYTO.V income_statement (annual, 2022-12-31) — Total Expenses: 792244.00
CYTO.V balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 238469.00
CYTO.V balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 935185.00
CYTO.V balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
CYTO.V balance_sheet (annual, 2022-12-31) — Working Capital: 2516200.00
CYTO.V income_statement (annual, 2023-12-31) — +Operating Expense: 4594032.00
CYTO.V income_statement (annual, 2023-12-31) — +Total Revenue: 0.00
CYTO.V balance_sheet (annual, 2023-12-31) — Accounts Payable: 361662.00
CYTO.V balance_sheet (annual, 2023-12-31) — Accounts Receivable: 264139.00
CYTO.V balance_sheet (annual, 2023-12-31) — Accrued Interest Receivable: 0.00
CYTO.V balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -1509750.00
CYTO.V income_statement (annual, 2023-12-31) — Basic Average Shares: 53753356.00
CYTO.V income_statement (annual, 2023-12-31) — Basic EPS: -0.09
CYTO.V cash_flow (annual, 2023-12-31) — Beginning Cash Position: 2246338.00
CYTO.V balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 2490299.00
CYTO.V cash_flow (annual, 2023-12-31) — Capital Expenditure: -162086.00
CYTO.V balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 1773992.00
CYTO.V balance_sheet (annual, 2023-12-31) — Capital Stock: 16178494.00
CYTO.V balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 31682.00
CYTO.V balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 31682.00
CYTO.V balance_sheet (annual, 2023-12-31) — Cash Equivalents: 0.00
CYTO.V balance_sheet (annual, 2023-12-31) — Cash Financial: 31682.00
CYTO.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: 3263316.00
CYTO.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -2619561.00
CYTO.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -2858411.00
CYTO.V cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 601521.00
CYTO.V cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -24791.00
CYTO.V cash_flow (annual, 2023-12-31) — Change In Receivables: -144630.00
CYTO.V cash_flow (annual, 2023-12-31) — Change In Working Capital: 432100.00
CYTO.V cash_flow (annual, 2023-12-31) — Changes In Account Receivables: -149720.00
CYTO.V cash_flow (annual, 2023-12-31) — Changes In Cash: -2214656.00
CYTO.V balance_sheet (annual, 2023-12-31) — Common Stock: 16178494.00
CYTO.V balance_sheet (annual, 2023-12-31) — Common Stock Equity: 372830.00
CYTO.V cash_flow (annual, 2023-12-31) — Common Stock Issuance: 522687.00
CYTO.V balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 409626.00
CYTO.V balance_sheet (annual, 2023-12-31) — Current Assets: 2952934.00
CYTO.V balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 348230.00
CYTO.V balance_sheet (annual, 2023-12-31) — Current Debt: 25110.00
CYTO.V balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 373340.00
CYTO.V balance_sheet (annual, 2023-12-31) — Current Deferred Assets: 42525.00
CYTO.V balance_sheet (annual, 2023-12-31) — Current Liabilities: 3644628.00
CYTO.V balance_sheet (annual, 2023-12-31) — Current Notes Payable: 25110.00
CYTO.V cash_flow (annual, 2023-12-31) — Depreciation: 512827.00
CYTO.V cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 512827.00
CYTO.V income_statement (annual, 2023-12-31) — Depreciation Amortization Depletion Income Statement: 512827.00
CYTO.V cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 512827.00
CYTO.V income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 512827.00
CYTO.V income_statement (annual, 2023-12-31) — Depreciation Income Statement: 512827.00
CYTO.V income_statement (annual, 2023-12-31) — Diluted Average Shares: 53753356.00
CYTO.V income_statement (annual, 2023-12-31) — Diluted EPS: -0.09
CYTO.V income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -4635417.00
CYTO.V income_statement (annual, 2023-12-31) — EBIT: -4601156.00
CYTO.V income_statement (annual, 2023-12-31) — EBITDA: -4088329.00
CYTO.V income_statement (annual, 2023-12-31) — Earnings From Equity Interest: -83470.00
CYTO.V cash_flow (annual, 2023-12-31) — End Cash Position: 31682.00
CYTO.V cash_flow (annual, 2023-12-31) — Financing Cash Flow: 3263316.00
CYTO.V cash_flow (annual, 2023-12-31) — Free Cash Flow: -3020497.00
CYTO.V balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: 3284199.00
CYTO.V income_statement (annual, 2023-12-31) — General And Administrative Expense: 3892642.00
CYTO.V balance_sheet (annual, 2023-12-31) — Gross PPE: 4000036.00
CYTO.V income_statement (annual, 2023-12-31) — Interest Expense: 34261.00
CYTO.V income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 34261.00
CYTO.V income_statement (annual, 2023-12-31) — Interest Income: 3786.00
CYTO.V income_statement (annual, 2023-12-31) — Interest Income Non Operating: 3786.00
CYTO.V cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 4643.00
CYTO.V cash_flow (annual, 2023-12-31) — Interest Received Cfi: 213577.00
CYTO.V balance_sheet (annual, 2023-12-31) — Invested Capital: 397940.00
CYTO.V cash_flow (annual, 2023-12-31) — Investing Cash Flow: -2619561.00
CYTO.V cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 522687.00
CYTO.V cash_flow (annual, 2023-12-31) — Issuance Of Debt: 25000.00
CYTO.V balance_sheet (annual, 2023-12-31) — Leases: 53300.00
CYTO.V balance_sheet (annual, 2023-12-31) — Loans Receivable: 25000.00
CYTO.V balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 1425762.00
CYTO.V balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 1425762.00
CYTO.V cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -211461.00
CYTO.V balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 272052.00
CYTO.V cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 0.00
CYTO.V cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 522687.00
CYTO.V income_statement (annual, 2023-12-31) — Net Income: -4635417.00
CYTO.V income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -4635417.00
CYTO.V income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -4635417.00
CYTO.V income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -4635417.00
CYTO.V income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -4635417.00
CYTO.V cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -4635417.00
CYTO.V income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -4635417.00
CYTO.V income_statement (annual, 2023-12-31) — Net Interest Income: -30475.00
CYTO.V cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: -57545.00
CYTO.V cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -186461.00
CYTO.V cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -211461.00
CYTO.V income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -30475.00
CYTO.V cash_flow (annual, 2023-12-31) — Net Other Financing Charges: 2454940.00
CYTO.V cash_flow (annual, 2023-12-31) — Net Other Investing Changes: -2457475.00
CYTO.V balance_sheet (annual, 2023-12-31) — Net PPE: 2490286.00
CYTO.V cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -162086.00
CYTO.V cash_flow (annual, 2023-12-31) — Net Short Term Debt Issuance: 25000.00
CYTO.V balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 372830.00
CYTO.V income_statement (annual, 2023-12-31) — Normalized EBITDA: -4077419.00
CYTO.V income_statement (annual, 2023-12-31) — Normalized Income: -4624507.00
CYTO.V cash_flow (annual, 2023-12-31) — Operating Cash Flow: -2858411.00
CYTO.V income_statement (annual, 2023-12-31) — Operating Income: -4594032.00
CYTO.V income_statement (annual, 2023-12-31) — Operating Revenue: 0.00
CYTO.V balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 53753356.00
CYTO.V balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 2500000.00
CYTO.V balance_sheet (annual, 2023-12-31) — Other Equity Interest: 1146389.00
CYTO.V income_statement (annual, 2023-12-31) — Other Gand A: 1136374.00
CYTO.V income_statement (annual, 2023-12-31) — Other Income Expense: -10910.00
CYTO.V cash_flow (annual, 2023-12-31) — Other Non Cash Items: 11020.00
CYTO.V income_statement (annual, 2023-12-31) — Other Operating Expenses: -101900.00
CYTO.V balance_sheet (annual, 2023-12-31) — Other Properties: 1184385.00
CYTO.V balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 5429081.00
CYTO.V income_statement (annual, 2023-12-31) — Other Special Charges: 10910.00
CYTO.V income_statement (annual, 2023-12-31) — Other Taxes: -151391.00
CYTO.V balance_sheet (annual, 2023-12-31) — Payables: 361662.00
CYTO.V balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 771288.00
CYTO.V balance_sheet (annual, 2023-12-31) — Prepaid Assets: 76647.00
CYTO.V income_statement (annual, 2023-12-31) — Pretax Income: -4635417.00
CYTO.V cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 472150.00
CYTO.V balance_sheet (annual, 2023-12-31) — Properties: 0.00
CYTO.V cash_flow (annual, 2023-12-31) — Purchase Of Investment: -5512545.00
CYTO.V cash_flow (annual, 2023-12-31) — Purchase Of PPE: -162086.00
CYTO.V balance_sheet (annual, 2023-12-31) — Receivables: 344605.00
CYTO.V income_statement (annual, 2023-12-31) — Reconciled Depreciation: 512827.00
CYTO.V cash_flow (annual, 2023-12-31) — Repayment Of Debt: -211461.00
CYTO.V income_statement (annual, 2023-12-31) — Research And Development: 441854.00
CYTO.V balance_sheet (annual, 2023-12-31) — Restricted Cash: 2457475.00
CYTO.V balance_sheet (annual, 2023-12-31) — Retained Earnings: -19089863.00
CYTO.V income_statement (annual, 2023-12-31) — Salaries And Wages: 2756268.00
CYTO.V cash_flow (annual, 2023-12-31) — Sale Of Business: 0.00
CYTO.V cash_flow (annual, 2023-12-31) — Sale Of Investment: 5455000.00
CYTO.V income_statement (annual, 2023-12-31) — Selling General And Administration: 3892642.00
CYTO.V balance_sheet (annual, 2023-12-31) — Share Issued: 53753356.00
CYTO.V cash_flow (annual, 2023-12-31) — Short Term Debt Issuance: 25000.00
CYTO.V income_statement (annual, 2023-12-31) — Special Income Charges: -10910.00
CYTO.V cash_flow (annual, 2023-12-31) — Stock Based Compensation: 821059.00
CYTO.V balance_sheet (annual, 2023-12-31) — Stockholders Equity: 372830.00
CYTO.V balance_sheet (annual, 2023-12-31) — Tangible Book Value: 372830.00
CYTO.V income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
CYTO.V income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.00
CYTO.V balance_sheet (annual, 2023-12-31) — Taxes Receivable: 80466.00
CYTO.V balance_sheet (annual, 2023-12-31) — Total Assets: 5443220.00
CYTO.V balance_sheet (annual, 2023-12-31) — Total Capitalization: 372830.00
CYTO.V balance_sheet (annual, 2023-12-31) — Total Debt: 1799102.00
CYTO.V balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 372830.00
CYTO.V income_statement (annual, 2023-12-31) — Total Expenses: 4594032.00
CYTO.V balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 5070390.00
CYTO.V balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 2490286.00
CYTO.V balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 1425762.00
CYTO.V income_statement (annual, 2023-12-31) — Total Unusual Items: -10910.00
CYTO.V income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -10910.00
CYTO.V balance_sheet (annual, 2023-12-31) — Working Capital: -691694.00
CYTO.V balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 165569.00
CYTO.V income_statement (quarterly, 2024-09-30) — Basic Average Shares: 53833786.00
CYTO.V income_statement (quarterly, 2024-09-30) — Basic EPS: -0.02
CYTO.V cash_flow (quarterly, 2024-09-30) — Capital Expenditure: -363649.00
CYTO.V cash_flow (quarterly, 2024-09-30) — Change In Other Working Capital: 0.00
CYTO.V balance_sheet (quarterly, 2024-09-30) — Current Deferred Assets: 0.00
CYTO.V balance_sheet (quarterly, 2024-09-30) — Current Notes Payable: 0.00
CYTO.V income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 53833786.00
CYTO.V income_statement (quarterly, 2024-09-30) — Diluted EPS: -0.02
CYTO.V income_statement (quarterly, 2024-09-30) — Interest Income: 33952.00
CYTO.V income_statement (quarterly, 2024-09-30) — Interest Income Non Operating: 33952.00
CYTO.V cash_flow (quarterly, 2024-09-30) — Interest Paid Supplemental Data: 0.00
CYTO.V cash_flow (quarterly, 2024-09-30) — Net Other Financing Charges: 0.00
CYTO.V cash_flow (quarterly, 2024-09-30) — Net Other Investing Changes: 0.00
CYTO.V cash_flow (quarterly, 2024-09-30) — Other Non Cash Items: -9049.00
CYTO.V income_statement (quarterly, 2024-09-30) — Other Taxes: 0.00
CYTO.V cash_flow (quarterly, 2024-09-30) — Proceeds From Stock Option Exercised: 0.00
CYTO.V balance_sheet (quarterly, 2024-09-30) — Restricted Cash: 0.00
CYTO.V cash_flow (quarterly, 2024-09-30) — Stock Based Compensation: 0.00
CYTO.V income_statement (annual, 2024-12-31) — +Operating Expense: 5154191.00
CYTO.V income_statement (quarterly, 2024-12-31) — +Operating Expense: 1176198.00
CYTO.V income_statement (annual, 2024-12-31) — +Total Revenue: 0.00
CYTO.V income_statement (quarterly, 2024-12-31) — +Total Revenue: 0.00
CYTO.V balance_sheet (annual, 2024-12-31) — Accounts Payable: 208947.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Accounts Payable: 208947.00
CYTO.V balance_sheet (annual, 2024-12-31) — Accounts Receivable: 0.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Accounts Receivable: 0.00
CYTO.V balance_sheet (annual, 2024-12-31) — Accrued Interest Receivable: 10092.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Accrued Interest Receivable: 10092.00
CYTO.V balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -1512534.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -1512534.00
CYTO.V income_statement (annual, 2024-12-31) — Basic Average Shares: 52834198.00
CYTO.V income_statement (annual, 2024-12-31) — Basic EPS: -0.15
CYTO.V cash_flow (annual, 2024-12-31) — Beginning Cash Position: 31682.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Beginning Cash Position: 2350149.00
CYTO.V balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 1811449.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Buildings And Improvements: 1811449.00
CYTO.V cash_flow (annual, 2024-12-31) — Capital Expenditure: -1304780.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Capital Expenditure: -100025.00
CYTO.V balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 1538149.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Capital Lease Obligations: 1538149.00
CYTO.V balance_sheet (annual, 2024-12-31) — Capital Stock: 25282687.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Capital Stock: 25282687.00
CYTO.V balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 1520755.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Cash And Cash Equivalents: 1520755.00
CYTO.V balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 1520755.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 1520755.00
CYTO.V balance_sheet (annual, 2024-12-31) — Cash Equivalents: 1066589.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Cash Equivalents: 1066589.00
CYTO.V balance_sheet (annual, 2024-12-31) — Cash Financial: 454166.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Cash Financial: 454166.00
CYTO.V cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -59948.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Financing Activities: 252665.00
CYTO.V cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: 6318743.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Investing Activities: -325025.00
CYTO.V cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -4769722.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Operating Activities: -757034.00
CYTO.V cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: -422682.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Change In Payables And Accrued Expense: 177706.00
CYTO.V cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: -21880.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Change In Prepaid Assets: 8471.00
CYTO.V cash_flow (annual, 2024-12-31) — Change In Receivables: 140249.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Change In Receivables: 199099.00
CYTO.V cash_flow (annual, 2024-12-31) — Change In Working Capital: -304313.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Change In Working Capital: -2305103.00
CYTO.V cash_flow (annual, 2024-12-31) — Changes In Account Receivables: 254047.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Changes In Account Receivables: 146063.00
CYTO.V cash_flow (annual, 2024-12-31) — Changes In Cash: 1489073.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Changes In Cash: -829394.00
CYTO.V balance_sheet (annual, 2024-12-31) — Common Stock: 25282687.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Common Stock: 25282687.00
CYTO.V balance_sheet (annual, 2024-12-31) — Common Stock Equity: 2931215.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Common Stock Equity: 2931215.00
CYTO.V cash_flow (annual, 2024-12-31) — Common Stock Issuance: 0.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Common Stock Issuance: -2500000.00
CYTO.V balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 259649.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Current Accrued Expenses: 259649.00
CYTO.V balance_sheet (annual, 2024-12-31) — Current Assets: 1824528.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Current Assets: 1824528.00
CYTO.V balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 215026.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Current Capital Lease Obligation: 215026.00
CYTO.V balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 215026.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Current Debt And Capital Lease Obligation: 215026.00
CYTO.V balance_sheet (annual, 2024-12-31) — Current Deferred Assets: 0.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Current Deferred Assets: 0.00
CYTO.V balance_sheet (annual, 2024-12-31) — Current Liabilities: 683622.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Current Liabilities: 683622.00
CYTO.V balance_sheet (annual, 2024-12-31) — Current Notes Payable: 0.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Current Notes Payable: 0.00
CYTO.V cash_flow (annual, 2024-12-31) — Depreciation: 707256.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Depreciation: 178350.00
CYTO.V cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 707256.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Depreciation Amortization Depletion: 178350.00
CYTO.V income_statement (annual, 2024-12-31) — Depreciation Amortization Depletion Income Statement: 707256.00
CYTO.V income_statement (quarterly, 2024-12-31) — Depreciation Amortization Depletion Income Statement: 178350.00
CYTO.V cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 707256.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Depreciation And Amortization: 178350.00
CYTO.V income_statement (annual, 2024-12-31) — Depreciation And Amortization In Income Statement: 707256.00
CYTO.V income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 178350.00
CYTO.V income_statement (annual, 2024-12-31) — Depreciation Income Statement: 707256.00
CYTO.V income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 178350.00
CYTO.V income_statement (annual, 2024-12-31) — Diluted Average Shares: 52834198.00
CYTO.V income_statement (annual, 2024-12-31) — Diluted EPS: -0.15
CYTO.V income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -7862699.00
CYTO.V income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: -1242544.00
CYTO.V income_statement (annual, 2024-12-31) — EBIT: -7760491.00
CYTO.V income_statement (quarterly, 2024-12-31) — EBIT: -1218376.00
CYTO.V income_statement (annual, 2024-12-31) — EBITDA: -7053235.00
CYTO.V income_statement (quarterly, 2024-12-31) — EBITDA: -1040026.00
CYTO.V cash_flow (annual, 2024-12-31) — End Cash Position: 1520755.00
CYTO.V cash_flow (quarterly, 2024-12-31) — End Cash Position: 1520755.00
CYTO.V cash_flow (annual, 2024-12-31) — Financing Cash Flow: -59948.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Financing Cash Flow: 252665.00
CYTO.V cash_flow (annual, 2024-12-31) — Free Cash Flow: -6074502.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Free Cash Flow: -857059.00
CYTO.V balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: 4211020.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: 4211020.00
CYTO.V income_statement (annual, 2024-12-31) — General And Administrative Expense: 4296079.00
CYTO.V income_statement (quarterly, 2024-12-31) — General And Administrative Expense: 974956.00
CYTO.V balance_sheet (annual, 2024-12-31) — Gross PPE: 4625966.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Gross PPE: 4625966.00
CYTO.V income_statement (annual, 2024-12-31) — Interest Expense: 102208.00
CYTO.V income_statement (quarterly, 2024-12-31) — Interest Expense: 24168.00
CYTO.V income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 102208.00
CYTO.V income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 24168.00
CYTO.V income_statement (annual, 2024-12-31) — Interest Income: 142160.00
CYTO.V income_statement (quarterly, 2024-12-31) — Interest Income: 13701.00
CYTO.V income_statement (annual, 2024-12-31) — Interest Income Non Operating: 142160.00
CYTO.V income_statement (quarterly, 2024-12-31) — Interest Income Non Operating: 13701.00
CYTO.V cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 102208.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Interest Paid Supplemental Data: 102208.00
CYTO.V balance_sheet (annual, 2024-12-31) — Invested Capital: 2931215.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Invested Capital: 2931215.00
CYTO.V cash_flow (annual, 2024-12-31) — Investing Cash Flow: 6318743.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Investing Cash Flow: -325025.00
CYTO.V cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 0.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Issuance Of Capital Stock: -2500000.00
CYTO.V cash_flow (annual, 2024-12-31) — Issuance Of Debt: 225000.00
CYTO.V balance_sheet (annual, 2024-12-31) — Leases: 1034588.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Leases: 1034588.00
CYTO.V balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 1323123.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Long Term Capital Lease Obligation: 1323123.00
CYTO.V balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 1323123.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 1323123.00
CYTO.V cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -261197.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Long Term Debt Payments: 27665.00
CYTO.V balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 497564.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 497564.00
CYTO.V cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 5166048.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Net Business Purchase And Sale: -225000.00
CYTO.V cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 0.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Net Common Stock Issuance: -2500000.00
CYTO.V income_statement (annual, 2024-12-31) — Net Income: -7862699.00
CYTO.V income_statement (quarterly, 2024-12-31) — Net Income: -1242544.00
CYTO.V income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -7862699.00
CYTO.V income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: -1242544.00
CYTO.V income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -7862699.00
CYTO.V income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: -1242544.00
CYTO.V income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -7862699.00
CYTO.V income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -1242544.00
CYTO.V income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -7862699.00
CYTO.V income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -1242544.00
CYTO.V cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -7862699.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Net Income From Continuing Operations: -1242544.00
CYTO.V income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -7862699.00
CYTO.V income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: -1242544.00
CYTO.V income_statement (annual, 2024-12-31) — Net Interest Income: 39952.00
CYTO.V income_statement (quarterly, 2024-12-31) — Net Interest Income: -10467.00
CYTO.V cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -36197.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Net Issuance Payments Of Debt: 252665.00
CYTO.V cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -261197.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Net Long Term Debt Issuance: 27665.00
CYTO.V income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 39952.00
CYTO.V income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -10467.00
CYTO.V cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -28751.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Net Other Financing Charges: 2500000.00
CYTO.V cash_flow (annual, 2024-12-31) — Net Other Investing Changes: 2457475.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Net Other Investing Changes: 0.00
CYTO.V balance_sheet (annual, 2024-12-31) — Net PPE: 3113432.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Net PPE: 3113432.00
CYTO.V cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -1304780.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Net PPE Purchase And Sale: -100025.00
CYTO.V cash_flow (annual, 2024-12-31) — Net Short Term Debt Issuance: 225000.00
CYTO.V balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 2931215.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Net Tangible Assets: 2931215.00
CYTO.V income_statement (annual, 2024-12-31) — Normalized EBITDA: -4293524.00
CYTO.V income_statement (quarterly, 2024-12-31) — Normalized EBITDA: -972896.00
CYTO.V income_statement (annual, 2024-12-31) — Normalized Income: -5102988.00
CYTO.V income_statement (quarterly, 2024-12-31) — Normalized Income: -1175414.00
CYTO.V cash_flow (annual, 2024-12-31) — Operating Cash Flow: -4769722.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Operating Cash Flow: -757034.00
CYTO.V income_statement (annual, 2024-12-31) — Operating Income: -5154191.00
CYTO.V income_statement (quarterly, 2024-12-31) — Operating Income: -1176198.00
CYTO.V income_statement (annual, 2024-12-31) — Operating Revenue: 0.00
CYTO.V income_statement (quarterly, 2024-12-31) — Operating Revenue: 0.00
CYTO.V balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 53935221.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Ordinary Shares Number: 53935221.00
CYTO.V income_statement (annual, 2024-12-31) — Other Gand A: 1678036.00
CYTO.V income_statement (quarterly, 2024-12-31) — Other Gand A: 316416.00
CYTO.V income_statement (annual, 2024-12-31) — Other Income Expense: -2748460.00
CYTO.V income_statement (quarterly, 2024-12-31) — Other Income Expense: -55879.00
CYTO.V cash_flow (annual, 2024-12-31) — Other Non Cash Items: 2690034.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Other Non Cash Items: 2612263.00
CYTO.V income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 11251.00
CYTO.V income_statement (annual, 2024-12-31) — Other Operating Expenses: 127988.00
CYTO.V income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 21666.00
CYTO.V balance_sheet (annual, 2024-12-31) — Other Properties: 1282365.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Other Properties: 1282365.00
CYTO.V income_statement (annual, 2024-12-31) — Other Special Charges: 2759711.00
CYTO.V income_statement (quarterly, 2024-12-31) — Other Special Charges: 67130.00
CYTO.V income_statement (annual, 2024-12-31) — Other Taxes: 0.00
CYTO.V balance_sheet (annual, 2024-12-31) — Payables: 208947.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Payables: 208947.00
CYTO.V balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 468596.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Payables And Accrued Expenses: 468596.00
CYTO.V balance_sheet (annual, 2024-12-31) — Prepaid Assets: 99417.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 99417.00
CYTO.V income_statement (annual, 2024-12-31) — Pretax Income: -7862699.00
CYTO.V income_statement (quarterly, 2024-12-31) — Pretax Income: -1242544.00
CYTO.V cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 5000.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Proceeds From Stock Option Exercised: 0.00
CYTO.V balance_sheet (annual, 2024-12-31) — Properties: 0.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
CYTO.V cash_flow (annual, 2024-12-31) — Purchase Of PPE: -1304780.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Purchase Of PPE: -100025.00
CYTO.V balance_sheet (annual, 2024-12-31) — Receivables: 204356.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Receivables: 204356.00
CYTO.V income_statement (annual, 2024-12-31) — Reconciled Depreciation: 707256.00
CYTO.V income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 178350.00
CYTO.V cash_flow (annual, 2024-12-31) — Repayment Of Debt: -261197.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Repayment Of Debt: 27665.00
CYTO.V income_statement (annual, 2024-12-31) — Research And Development: 22868.00
CYTO.V income_statement (quarterly, 2024-12-31) — Research And Development: 1226.00
CYTO.V balance_sheet (annual, 2024-12-31) — Restricted Cash: 0.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Restricted Cash: 0.00
CYTO.V balance_sheet (annual, 2024-12-31) — Retained Earnings: -26562492.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Retained Earnings: -26562492.00
CYTO.V income_statement (annual, 2024-12-31) — Salaries And Wages: 2618043.00
CYTO.V income_statement (quarterly, 2024-12-31) — Salaries And Wages: 658540.00
CYTO.V cash_flow (annual, 2024-12-31) — Sale Of Business: 5166048.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Sale Of Business: -225000.00
CYTO.V income_statement (annual, 2024-12-31) — Selling General And Administration: 4296079.00
CYTO.V income_statement (quarterly, 2024-12-31) — Selling General And Administration: 974956.00
CYTO.V balance_sheet (annual, 2024-12-31) — Share Issued: 53935221.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Share Issued: 53935221.00
CYTO.V cash_flow (annual, 2024-12-31) — Short Term Debt Issuance: 225000.00
CYTO.V income_statement (annual, 2024-12-31) — Special Income Charges: -2759711.00
CYTO.V income_statement (quarterly, 2024-12-31) — Special Income Charges: -67130.00
CYTO.V cash_flow (annual, 2024-12-31) — Stock Based Compensation: 0.00
CYTO.V cash_flow (quarterly, 2024-12-31) — Stock Based Compensation: 0.00
CYTO.V balance_sheet (annual, 2024-12-31) — Stockholders Equity: 2931215.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Stockholders Equity: 2931215.00
CYTO.V balance_sheet (annual, 2024-12-31) — Tangible Book Value: 2931215.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Tangible Book Value: 2931215.00
CYTO.V income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
CYTO.V income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
CYTO.V income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.00
CYTO.V income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.00
CYTO.V balance_sheet (annual, 2024-12-31) — Taxes Receivable: 194264.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Taxes Receivable: 194264.00
CYTO.V balance_sheet (annual, 2024-12-31) — Total Assets: 4937960.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Total Assets: 4937960.00
CYTO.V balance_sheet (annual, 2024-12-31) — Total Capitalization: 2931215.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Total Capitalization: 2931215.00
CYTO.V balance_sheet (annual, 2024-12-31) — Total Debt: 1538149.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Total Debt: 1538149.00
CYTO.V balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 2931215.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Total Equity Gross Minority Interest: 2931215.00
CYTO.V income_statement (annual, 2024-12-31) — Total Expenses: 5154191.00
CYTO.V income_statement (quarterly, 2024-12-31) — Total Expenses: 1176198.00
CYTO.V balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 2006745.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Total Liabilities Net Minority Interest: 2006745.00
CYTO.V balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 3113432.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Total Non Current Assets: 3113432.00
CYTO.V balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 1323123.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 1323123.00
CYTO.V income_statement (annual, 2024-12-31) — Total Unusual Items: -2759711.00
CYTO.V income_statement (quarterly, 2024-12-31) — Total Unusual Items: -67130.00
CYTO.V income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -2759711.00
CYTO.V income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: -67130.00
CYTO.V balance_sheet (annual, 2024-12-31) — Working Capital: 1140906.00
CYTO.V balance_sheet (quarterly, 2024-12-31) — Working Capital: 1140906.00
CYTO.V income_statement (quarterly, 2025-03-31) — +Operating Expense: 1139959.00
CYTO.V income_statement (quarterly, 2025-03-31) — +Total Revenue: 0.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 313664.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 13471.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Accrued Interest Receivable: 9552.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -1767347.00
CYTO.V income_statement (quarterly, 2025-03-31) — Basic Average Shares: 53935221.00
CYTO.V income_statement (quarterly, 2025-03-31) — Basic EPS: -0.02
CYTO.V cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 1520755.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 1811449.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -3139.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 1486885.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Capital Stock: 25282687.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 714981.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 714981.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 566589.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Cash Financial: 148392.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -74621.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -3139.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -728014.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 54485.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -5873.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Change In Receivables: 105382.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 153994.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: -12931.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Changes In Cash: -805774.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Common Stock: 25282687.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 1771037.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 0.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 209417.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Current Assets: 919245.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 223517.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 223517.00
CYTO.V balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 746597.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Depreciation: 254813.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 254813.00
CYTO.V income_statement (quarterly, 2025-03-31) — Depreciation Amortization Depletion Income Statement: 254813.00
CYTO.V cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 254813.00
CYTO.V income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 254813.00
CYTO.V income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 254813.00
CYTO.V income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 53935221.00
CYTO.V income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.02
CYTO.V income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -1160178.00
CYTO.V income_statement (quarterly, 2025-03-31) — EBIT: -1135441.00
CYTO.V income_statement (quarterly, 2025-03-31) — EBITDA: -880628.00
CYTO.V cash_flow (quarterly, 2025-03-31) — End Cash Position: 714981.00